# Acadia Pharmaceuticals (ACAD) — Overview

ACAD · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/acad

## Price

Last close $19.71 on Oct 15, 2026. 52-week range $18.62 – $30.57.

## Company profile

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

## Financials

| Metric | Value |
| --- | --- |
| Revenue (trailing twelve months) | $1.1B |
| Revenue (quarter) | $308.0M |
| Revenue growth (year over year) | 16.40% |
| Gross profit (trailing twelve months) | $1.0B |
| Gross margin | 91.13% |
| Net income (trailing twelve months) | $380.5M |
| Net income (quarter) | $31.5M |
| Net income growth (year over year) | 18.13% |
| Net margin | 33.42% |
| Return on equity | 35.74% |
| EPS (trailing twelve months) | $2.26 |
| Book value per share | $7.59 |
| P/E (trailing twelve months) | 8.9 |
| Price to book | 2.6 |
| Debt to assets | 25.03% |
| Payout ratio | 0.00% |
| Dividend yield | 0.00% |

## Frequently Asked Questions

### Is Acadia Pharmaceuticals (ACAD) profitable?

Yes. Acadia Pharmaceuticals earned $380.5M in net income over the trailing twelve months, a net margin of 33.42%.

### How much revenue does Acadia Pharmaceuticals (ACAD) make?

Acadia Pharmaceuticals generated $1.1B in revenue over the trailing twelve months, up 16.40% year over year.

### What is ACAD's P/E ratio?

Acadia Pharmaceuticals trades at 8.9 times trailing twelve-month earnings, on an EPS of $2.26.

### How do I buy stock in Acadia Pharmaceuticals (ACAD)?

ACAD trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at [Light Horse Dashboard](https://portal.lighthorse.io), the trading API, or an [AI agent connected over MCP](/instructions/ai/claude). The trade panel on this page places the order once you are signed in.

---

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).